- Home
- RDHL vs ADXN Comparison
RDHL vs ADXN Comparison
Compare RDHL & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- ADXN
- Stock Information
- Founded
- RDHL 2009
- ADXN 2002
- Country
- RDHL Israel
- ADXN Switzerland
- Employees
- RDHL N/A
- ADXN N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- ADXN Health Care
- Exchange
- RDHL Nasdaq
- ADXN Nasdaq
- Market Cap
- RDHL 4.3M
- ADXN 10.1M
- IPO Year
- RDHL N/A
- ADXN N/A
- Fundamental
- Price
- RDHL $2.15
- ADXN $8.83
- Analyst Decision
- RDHL
- ADXN Strong Buy
- Analyst Count
- RDHL 0
- ADXN 1
- Target Price
- RDHL N/A
- ADXN $30.00
- AVG Volume (30 Days)
- RDHL 18.4K
- ADXN 14.4K
- Earning Date
- RDHL 08-28-2025
- ADXN 08-11-2025
- Dividend Yield
- RDHL N/A
- ADXN N/A
- EPS Growth
- RDHL N/A
- ADXN N/A
- EPS
- RDHL N/A
- ADXN 0.10
- Revenue
- RDHL $8,042,999.00
- ADXN $278,508.00
- Revenue This Year
- RDHL $381.91
- ADXN $86.57
- Revenue Next Year
- RDHL N/A
- ADXN N/A
- P/E Ratio
- RDHL N/A
- ADXN $0.78
- Revenue Growth
- RDHL 23.17
- ADXN N/A
- 52 Week Low
- RDHL $1.71
- ADXN $6.51
- 52 Week High
- RDHL $20.28
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- RDHL 64.10
- ADXN 49.41
- Support Level
- RDHL $2.00
- ADXN $8.78
- Resistance Level
- RDHL $2.08
- ADXN $9.89
- Average True Range (ATR)
- RDHL 0.09
- ADXN 0.67
- MACD
- RDHL 0.03
- ADXN -0.03
- Stochastic Oscillator
- RDHL 100.00
- ADXN 43.01
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.